"To test a new treatment, you need to take it through a Phase 3 clinical trial. That's typically 10 years and $2 billion. To test a diagnostic, you need to demonstrate clinical benefit, pass a rigorous third-party test, and build a full quality management system-before your product is even permitted into the clinic."
"The industry needs to close the gap between where AI models are trained and where medicine actually happens. This hard work is what the best AI companies in the field are doing."
"Bringing your AI to patients has a big upside: It forces your AI to be better. From our experience, we've had to tackle unexpected, knotty problems."
Many AI companies in healthcare, like Alphabet's Isomorphic and Lila, make ambitious claims about their capabilities. However, the true measure of success lies in whether these technologies have produced effective treatments for humans. The process of developing new medicines is complex and lengthy, often requiring extensive clinical trials and rigorous testing. Companies like Insilico Medicine and Recursion are making strides by advancing AI-discovered treatments through clinical trials, demonstrating that real-world application is essential for AI improvement and success in healthcare.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]